Friday, September 9, 2022

08.25 – 08.30 hrs   Welcome by EHMSG President Georgina Hold

08.30 – 09.30 hrs   Session 1 - Introductory Lectures 

Chair: Georgina Hold, Australia & Colm O’Morain, Ireland & Anthony Axon, United Kingdom


08.30 - 09.00

Role of H. pylori at the gastro-esophageal junction
Ken McColl, Glasgow, United Kingdom


09.00 - 09.30

Dialogue between H. pylori and the gut microbiota
Emad El Omar, Sydney, Australia


09.30 – 11.00 hrs   Session 2 -  Maastricht VI

Chair: Peter Malfertheiner, Germany & Richard Hunt, Canada/United Kingdom


09.30 - 09.42
The  consensus concept            
Peter Malfertheiner, Munich, Germany

09.42 - 09.54
H. pylori infection in gastroduodenal and extragastric diseases
Theodore Rokkas, Athens, Greece


09.54 - 10.06
New Demands in H. pylori diagnosis  
Francis Mégraud, Bordeaux, France          

10.06 - 10.18
Therapy of H. pylori infection in evolution      
Javier Gisbert, Madrid, Spain                         

10.18 - 10.30
H. pylori screening in the prevention medicine                                                    
Jhy Ming Liou, Taipei, Taiwan


10.30 - 10.42
H. pylori in the relationship with other gastric microbiota      
Antonio Gasbarrini, Rome, Italy           


10.42 - 10.54
H. pylori treatment and the impact on gut microbiota
Christian Schulz, Munich, Germany

11.00 - 11.30 hrs  Coffee Break

11.30 – 13.00   Session 3 -  Gastric carcinogenesis

Chair: José Machado, Portugal & Jung Hwoon-Yong, Ulsan, South Korea


11.30 - 11.50
The human stomach epithelial homeostasis recapitulated in-vitro by using mucosoid cultures

Francesco Boccellato, Oxford, UK

11.50 - 12.10
Utility of preclinical models to understand carcinogenesis

Michael Sigal, Berlin, Germany

12.10 - 12.30
Autophagy is necessary for gastric cancer stem cell emergence

Emilie Bessede, Bordeaux, France

12.30 - 12.50
Autoimmune atrophic gastritis and gastric cancer
Marino Venerito, Magdeburg, Germany

13.00 – 14.00 hrs   Lunch Break & Poster Viewing

14.00 – 15.40 hrs   Session 4 - Microbiota

Chair: Richard Hansen, United Kingdom & Jae Gyu Kim, Seoul, South Korea


14.00 - 14.20
Gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice

Yong-Chang Lee, Seoul, Korea

14.20 - 14.40
Establishment of gut microbiota in humans
Hakdong Shin, Seoul, Korea


14.40 - 15.00
Use of registers in microbiota research
Nele Brusselaers, Stockholm, Sweden


15.00 - 15.20
Bidirectional crosstalk between mucins and the microbiota at the level of the GI epithelium
Annemieke Smet, Antwerp, Belgium


15.20 - 15.40
New microbiota therapeutics
Harry Sokol, Paris, France


15.45 – 17.15 hrs   Session 5 - Parallel Workshops from Submitted Abstracts W1

Microbiota in Health and Disease

Chair: Georgina Hold, Sydney, Australia & Antonio Gasbarrini, Rome, Italy

15.45 – 16.00   

Aging and shared household are the main determinant of the gut microbial similarity in twins 

Alexander Link, Magdeburg, Germany


16.00 – 16.15

Whole Metagenome Shotgun Sequencing as a Next-Generation Sequencing Approach to Characterize the Taxonomy and Functional Risk Factors of the Gastric Microbiome

Anthony Mannion, Cambridge, United States


16.15 – 16.30

Implementation of a metatranscriptomics strategy for functional profiling of the gastric cancer microbiome

Rui Ferreira, Porto, Portugal


16.30 – 16.45

Relationships of the gut microbiome with cognitive development among healthy school age children

Khitam Muhsen, Tel Aviv, Israel


16.45 – 17.00

Association of stomach microbiome with prognosis of gastric cancer patients

Konrad Lehr, Magdeburg, Germany


17.00 – 17.15

Microbiome signature of metabolically healthy obese individuals according to anthropometric, metabolic and inflammatory parameters

Nam-Eun Kim, Seoungnam-si, Republic of Korea 

15.45 – 17.15 hrs   Session 6 - Parallel Workshops from Submitted Abstracts W2

Diagnosis, Epidemiology, Extragastric Disease

Chair: Stella Smith, Lagos, Nigeria & Francis Mégraud, Bordeaux, France

15.45 – 16.00

Helicobacter pylori outer membrane vesicles alter astrocyte and neuronal function in vitro and in vivo

Manuel Valenzuela-Valderrama, Santiago, Chile


16.00 – 16.15

Neurotoxic properties of Helicobacter pylori urease: a possible link to Alzheimer’s Disease?

Celia Carlini, Porto Alegre, Brazil


16.15 – 16.30

Helicobacter pylori diagnostic tests used in 35,000 patients in Europe: results from the European Registry on H. pylori Management (Hp-EuReg)

Laimas Jonaitis, Kaunas, Lithuania


16.30 – 16.45

Real-time assessment of H. pylori gastritis guided by Endofaster: a prospective cohort study.

Riccardo Vasapolli, Munich, Germany


16.45 – 17.00

Prevalence of and risk factors for familial Helicobacter pyloriinfection in China: a nationwide family-based cross-sectional study

Xianzhu Zhou, Shanghai, China


17.00 – 17.15

High incidence of resistance to antibiotics used for eradication of Helicobacter pyloriin the UK

Suffi Suffian, NOTTINGHAM, United Kingdom

17.15 – 17.45 hrs   Coffee Break


17.45 – 19.15 hrs   Session 7 - Parallel Workshops from Submitted Abstracts W3

Pathogenesis of Helicobacter pylori

Chair: Ari Ristimäki, Helsinki, Finland & Mark Pritchard, Liverpool, United Kingdom

17.45 – 18.00

Single-cell transcriptomics atlas of Helicobacter pylori infection-associated gastric carcinogenesis

Nianshuang Li, Nanchang, China


18.00 – 18.15

The cytolethal distending toxin modulates cell differentiation and elicits epithelial to mesenchymal transition

Lamia Azzi-Martin, Bordeaux, France


18.15 – 18.30

Effects of chronic Helicobacter pylori strain PMSS1 infection on whole brain and gastric iron homeostatsis in male INS-GAS mice

Hilda Holcombe, Cambridge, United States 


18.30 – 18.45

CD40-CD40L blockade attenuates disease in a new mouse model of gastric B cell MALT lymphoma

Richard Ferrero, Victoria, Australia

18.45 – 19.00

Th1 cytokines, especially TNF, cause NF-κB2 dependent morphological changes in primary mouse gastric organoids (gastroids)

Liwen Liu, Liverpool, United Kingdom


19.00 – 19.15

ACE2 is involved in the carcinogenic process of Helicobacter pylori infection

Huan Wang, Nanchang, China

17.45 – 19.15 hrs   Session 8 - Parallel Workshops from Submitted Abstracts W4

Treatment of Helicobacter pylori

Chair: Jan Bornschein, Oxford, United Kingdom & Francesco Franceschi, Rome, Italy

17.45 – 18.00

Mistakes in empirical eradication therapies for Helicobacter pylori in 45,778 patients: data from the European Registry on H. pylori management (Hp-EuReg)

Samuel J. Martínez-Domínguez, Zaragoza, Spain


18.00 – 18.15

H. pylori phages: from genome release to hope for use as therapy

Rute Ferreira, Braga, Portugal


18.15 – 18.30

Long-term changes of gut microbiota and antibiotic resistome after H. pylori eradication- a multicenter randomized trial

Jyh-Ming Liou, Taipei, Taiwan


18.30 – 18.45

Comparison of empirical first-line treatment between tegoprazan versus lansoprazole based quadruple therapy: double-blind randomized controlled trial

Jun-Won Chung, Incheon, Republic of Korea


18.45 – 19.00

Comparison of the effectiveness of Helicobacter pylori eradication regimens between the elderly and non-elderly populations: data from the European Registry on H. pylori management (Hp-EuReg)

Paulius Jonaitis, Kaunas, Lithuania


19.00 – 19.15

Pilot studies of Vonoprazan-containing Helicobacter pylori eradication therapy

Sarita Ratana-Amornpin, Pathumthani, Thailand



20.00 hrs                Networking Dinner

Saturday, September 10, 2022

08.00 – 09.30 hrs   Session 9 - Fecal Microbiota Transplantation (FMT)

Chair: Josbert Keller, Den Haag, The Netherlands, Christian Hvas, Aarhus, Denmark


08.00 - 08.05
Introduction: FMT: from C. difficile towards other indications
Josbert Keller, Leiden, The Netherlands


08.05 - 08.25
FMT and immunotherapy: to overcome resistance and to treat immunotherapy induced colitis
Gianluca Ianiro, Rome, Italy


08.25 - 08.40
FMT for Inflammatory Bowel diseases: timing and selection of patients and donors
Tariq Iqbal, Birmingham, United Kingdom

08.40 - 09.00
Encapsulation, life bacterial products and regulation
Christian Hvas, Aarhus, Denmark


09.00 - 09.15
Introduction of an FMT registry
Maria Vehreschild, Frankfurt, Germany


09.15 - 09.30
Investigations of serious adverse events after FMT    
Liz Terveer, Leiden, The Netherlands

09.30 – 10.00 hrs   Coffee Break

10.00 – 11.20 hrs   Session 10 - H. pylori diagnosis & treatment

Chair: Theodore Rokkas, Athens, Greece & Jong-Jae Park, Seoul, South Korea


10.00 - 10.20
New methods for antimicrobial susceptibility testing. The US experience

David Graham, Houston, Texas, USA

10.20 - 10.40
H. pylori rescue treatment. Data from the Hp-EuReg
Olga Nyssen, Madrid, Spain


10.40 - 11.00
Use of serum pepsinogen assays in clinical practice
Sun-Young Lee, Seoul, Korea


11.00 - 11.20
Impact of probiotics on the faecal resistome during H. pylori eradication
Marcis Leja, Riga, Latvia

11.20 – 12.20 hrs   Session 11 - Industry-Sponsored Satellite Symposium

Click here for more information

Chair: Colm O’Morain, Dublin, Ireland

12.20 – 13.20 hrs   Lunch Break & Poster Viewing

13.20 – 14.50 hrs   Session 12 - Parallel Workshops from Submitted Abstracts W5

Microbiota Manipulation

Chair: Giovanni Gasbarrini, Rome, Italy & Richard Hansen, Glasgow, United Kingdom

13.20 – 13.35

Effects of transplant dose, route of administration, and repeating on the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome

Magdy El-Salhy, Bergen, Norway


13.35 – 13.50

The effect of multi-strain probiotics on diarrhea in patients with type 2 diabetes and metformin intolerance

Katarzyna Nabrdalik, Zabrze, Poland


13.50 – 14.05

A microbiota targeted, Mediterranean diet-based nutritional education program positively modifies the intestinal microenvironment of healthy individuals

Tsachi Perets, Petah Tikva, Israel


14.05 – 14.20

Fecal microbiota transplantation (FMT) on irritable bowel syndrome (IBS): A randomized, placebo-controlled, double-blind study

Natsuda Aumpan, Pathumthani, Thailand


14.20 – 14.35

Immune and non immune changes following fecal microbiota transplantation in experimental colitis: emerging pathways of fmt derived mucosal healing

Valentina Petito, Rome, Italy


14.35 – 14.50

Changes in gut microbiota after antibacterial therapy among children: preliminary data

Ilva Daugule, Riga, Latvia

13.20 – 14.50 hrs   Session 13 - Parallel Workshops from Submitted Abstracts W6

Gastric Carcinogenesis

Chair: Yaron Niv, Pardesia, Israel & Karen Robinson, Nottingham, United Kingdom

13.20 – 13.35

Optimal Follow-Up Period after Endoscopic Resection of Early Gastric Cancer: A Multi-Center Retrospective Cohort Study
Byung-Wook Kim, Incheon, Republic of Korea


13.35 – 13.50

Atrophic gastritis and gastric cancer tissue miRNome analysis

Ruta Inciuraite, Kaunas, Lithuania


13.50 – 14.05

Helicobacter pylori testing among individuals at risk of gastric cancer: a potential interception point to reduce the gastric cancer burden in the US

Meira Epplein, Durham, United States 


14.05 – 14.20

Incidence of gastric cancer among long-term users of proton pump inhibitors after Helicobacter pylori eradication; a population-based cohort study in Korea

Jong Wook Kim, Goyang, Republic of Korea

14.20 – 14.35

Identification of serological markers associated with gastric cancer in two Chinese studies using Helicobacter pylori multi-strain microarrays

Rima Jeske, Heidelberg, Germany


14.35 – 14.50

Distinct mucin-microbiome signatures in patients with gastric cancer

Baptiste Oosterlinck, Antwerp, Belgium

14.50 – 15.20 hrs   Coffee Break

15.20 – 16.20 hrs   Session 14 - Potassium Competitive Acid Blockers (P-CABs)

Chair: Kenneth McColl, Glasgow, United Kingdom & Javier Gisbert, Madrid, Spain


15.20 - 15.40
P-CAB performance from a network meta-analysis
Theodore Rokkas, Athens, Greece


15.40 - 16.00
Pharmacological and clinical properties of P-CABs
Colin Howden, Memphis, TN, USA


16.00 - 16.20
Long-term experience with P-CABs
Ken Sugano, Shimotsuke City, Japan

16.20 – 17.00 hrs   Session 15 - State of the Art lectures: Looking  to the future

Chair: Lars Engstrand, Stockholm, Sweden & Marcis Leja, Riga, Latvia


16.20 - 16.40
The BioCyc databases: pathways, omics tools and enhanced genome annotation
Ron Caspi, Menlo Park, CA, USA

16.40 - 17.00
New developments on gastric cancer treatment
Tamara Matysiak, Nantes, France


17.00 – 18.10 hrs   Session 16 - Closing Session

Chair: Annemieke Smet, Antwerp, Belgium & Georgina Hold, Sydney, Australia


17.00 - 17.20

The discovery of H. pylori viewed from the UK  Cliodna McNulty, Gloucester, UK

17.20 - 17.30

Awarding of the Marshall and Warren Medal 2022 to Massimo Rugge, Padova, Italy

17.30 - 17.40
Awarding of the Marshall and Warren Medal 2020 to Hazel Mitchell & 2021 to Dulciene Queiroz

17.40 - 17.50

Awarding of the EHMSG Oral and Poster Awards

17.50 - 18.00
Presentation of the EHMSG Journal

18.00 - 18.10

Presentation of the next meeting in Antwerp
Annemieke Smet, Antwerp, Belgium


Closing Remarks